Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients

Wen Sheng Huang, Yung Hsiao Chiang, Jiann Chyun Lin, Yuan Hwa Chou, Cheng Yi Cheng, Ren Shyan Liu

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

99mTc-TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8- azabicyclo[3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino] -ethanethiolato(3-)-N2,N2′,S2,S2′]oxo-[1R-(exo-exo)]) is a potential agent for dopamine transporter (DAT) SPECT, whereas 6-18F-fluoro-L- dopa (18F-FDOPA) PET has been used for the quantitative assessment of presynaptic nigrostriatal dopaminergic function. The current study investigated the relationship between the 2 imaging modalities in evaluating patients with Parkinson's disease (PD). Methods: Twenty patients in whom PD was diagnosed by generally accepted criteria were recruited. In addition to visual inspection, specific uptake ratios (SURs) of 99mTc-TRODAT-1 in the striatum and putamen were measured bilaterally. For PET, all patients received 100 mg of carbidopa 90 min before 18F-FDOPA (300 MBq) injection. Images were acquired between 120 and 150 min after injection, using a whole-body PET scanner with settings identical to those for the SPECT studies. The SURs for PET were calculated similarly to those for SPECT. Individual SURs of the striatum or putamen from SPECT were correlated with the corresponding PET values using linear regression. Results: A consistent image pattern between SPECT and PET was achieved by visual inspection except for 3 cases. In 1 case (a patient with Hoehn and Yahr Scale I PD), the SPECT images were more compatible with the patient's clinical findings whereas PET showed nearly normal uptake. In the other 2 cases (both patients with Hoehn and Yahr Scale II PD), PET correlated better with the clinical findings. The caudate and putamen nuclei were more discernable on PET. An acceptable correlation of SUR, however, was found between SPECT and PET in both the striatum and the putamen (P <0.01 for both). Conclusion: The comparability of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET suggests that 99mTc-TRODAT-1 SPECT may provide a reliable alternative to 18F-FDOPA PET in the evaluation of clinical PD patients.

Original languageEnglish
Pages (from-to)999-1005
Number of pages7
JournalJournal of Nuclear Medicine
Volume44
Issue number7
Publication statusPublished - Jul 2003
Externally publishedYes

Fingerprint

Levodopa
Single-Photon Emission-Computed Tomography
Cross-Over Studies
Parkinson Disease
Putamen
Carbidopa
technetium Tc 99m TRODAT-1
Dopamine Plasma Membrane Transport Proteins
Injections
Caudate Nucleus
Linear Models

Keywords

  • 6-F-fluoro-L-dopa PET
  • Tc-TRODAT-1 SPECT
  • Parkinson's disease

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Huang, W. S., Chiang, Y. H., Lin, J. C., Chou, Y. H., Cheng, C. Y., & Liu, R. S. (2003). Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients. Journal of Nuclear Medicine, 44(7), 999-1005.

Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients. / Huang, Wen Sheng; Chiang, Yung Hsiao; Lin, Jiann Chyun; Chou, Yuan Hwa; Cheng, Cheng Yi; Liu, Ren Shyan.

In: Journal of Nuclear Medicine, Vol. 44, No. 7, 07.2003, p. 999-1005.

Research output: Contribution to journalArticle

Huang, WS, Chiang, YH, Lin, JC, Chou, YH, Cheng, CY & Liu, RS 2003, 'Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients', Journal of Nuclear Medicine, vol. 44, no. 7, pp. 999-1005.
Huang, Wen Sheng ; Chiang, Yung Hsiao ; Lin, Jiann Chyun ; Chou, Yuan Hwa ; Cheng, Cheng Yi ; Liu, Ren Shyan. / Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients. In: Journal of Nuclear Medicine. 2003 ; Vol. 44, No. 7. pp. 999-1005.
@article{13dbc4b9e27444e68497adf75e2768b4,
title = "Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients",
abstract = "99mTc-TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8- azabicyclo[3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino] -ethanethiolato(3-)-N2,N2′,S2,S2′]oxo-[1R-(exo-exo)]) is a potential agent for dopamine transporter (DAT) SPECT, whereas 6-18F-fluoro-L- dopa (18F-FDOPA) PET has been used for the quantitative assessment of presynaptic nigrostriatal dopaminergic function. The current study investigated the relationship between the 2 imaging modalities in evaluating patients with Parkinson's disease (PD). Methods: Twenty patients in whom PD was diagnosed by generally accepted criteria were recruited. In addition to visual inspection, specific uptake ratios (SURs) of 99mTc-TRODAT-1 in the striatum and putamen were measured bilaterally. For PET, all patients received 100 mg of carbidopa 90 min before 18F-FDOPA (300 MBq) injection. Images were acquired between 120 and 150 min after injection, using a whole-body PET scanner with settings identical to those for the SPECT studies. The SURs for PET were calculated similarly to those for SPECT. Individual SURs of the striatum or putamen from SPECT were correlated with the corresponding PET values using linear regression. Results: A consistent image pattern between SPECT and PET was achieved by visual inspection except for 3 cases. In 1 case (a patient with Hoehn and Yahr Scale I PD), the SPECT images were more compatible with the patient's clinical findings whereas PET showed nearly normal uptake. In the other 2 cases (both patients with Hoehn and Yahr Scale II PD), PET correlated better with the clinical findings. The caudate and putamen nuclei were more discernable on PET. An acceptable correlation of SUR, however, was found between SPECT and PET in both the striatum and the putamen (P <0.01 for both). Conclusion: The comparability of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET suggests that 99mTc-TRODAT-1 SPECT may provide a reliable alternative to 18F-FDOPA PET in the evaluation of clinical PD patients.",
keywords = "6-F-fluoro-L-dopa PET, Tc-TRODAT-1 SPECT, Parkinson's disease",
author = "Huang, {Wen Sheng} and Chiang, {Yung Hsiao} and Lin, {Jiann Chyun} and Chou, {Yuan Hwa} and Cheng, {Cheng Yi} and Liu, {Ren Shyan}",
year = "2003",
month = "7",
language = "English",
volume = "44",
pages = "999--1005",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients

AU - Huang, Wen Sheng

AU - Chiang, Yung Hsiao

AU - Lin, Jiann Chyun

AU - Chou, Yuan Hwa

AU - Cheng, Cheng Yi

AU - Liu, Ren Shyan

PY - 2003/7

Y1 - 2003/7

N2 - 99mTc-TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8- azabicyclo[3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino] -ethanethiolato(3-)-N2,N2′,S2,S2′]oxo-[1R-(exo-exo)]) is a potential agent for dopamine transporter (DAT) SPECT, whereas 6-18F-fluoro-L- dopa (18F-FDOPA) PET has been used for the quantitative assessment of presynaptic nigrostriatal dopaminergic function. The current study investigated the relationship between the 2 imaging modalities in evaluating patients with Parkinson's disease (PD). Methods: Twenty patients in whom PD was diagnosed by generally accepted criteria were recruited. In addition to visual inspection, specific uptake ratios (SURs) of 99mTc-TRODAT-1 in the striatum and putamen were measured bilaterally. For PET, all patients received 100 mg of carbidopa 90 min before 18F-FDOPA (300 MBq) injection. Images were acquired between 120 and 150 min after injection, using a whole-body PET scanner with settings identical to those for the SPECT studies. The SURs for PET were calculated similarly to those for SPECT. Individual SURs of the striatum or putamen from SPECT were correlated with the corresponding PET values using linear regression. Results: A consistent image pattern between SPECT and PET was achieved by visual inspection except for 3 cases. In 1 case (a patient with Hoehn and Yahr Scale I PD), the SPECT images were more compatible with the patient's clinical findings whereas PET showed nearly normal uptake. In the other 2 cases (both patients with Hoehn and Yahr Scale II PD), PET correlated better with the clinical findings. The caudate and putamen nuclei were more discernable on PET. An acceptable correlation of SUR, however, was found between SPECT and PET in both the striatum and the putamen (P <0.01 for both). Conclusion: The comparability of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET suggests that 99mTc-TRODAT-1 SPECT may provide a reliable alternative to 18F-FDOPA PET in the evaluation of clinical PD patients.

AB - 99mTc-TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8- azabicyclo[3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino] -ethanethiolato(3-)-N2,N2′,S2,S2′]oxo-[1R-(exo-exo)]) is a potential agent for dopamine transporter (DAT) SPECT, whereas 6-18F-fluoro-L- dopa (18F-FDOPA) PET has been used for the quantitative assessment of presynaptic nigrostriatal dopaminergic function. The current study investigated the relationship between the 2 imaging modalities in evaluating patients with Parkinson's disease (PD). Methods: Twenty patients in whom PD was diagnosed by generally accepted criteria were recruited. In addition to visual inspection, specific uptake ratios (SURs) of 99mTc-TRODAT-1 in the striatum and putamen were measured bilaterally. For PET, all patients received 100 mg of carbidopa 90 min before 18F-FDOPA (300 MBq) injection. Images were acquired between 120 and 150 min after injection, using a whole-body PET scanner with settings identical to those for the SPECT studies. The SURs for PET were calculated similarly to those for SPECT. Individual SURs of the striatum or putamen from SPECT were correlated with the corresponding PET values using linear regression. Results: A consistent image pattern between SPECT and PET was achieved by visual inspection except for 3 cases. In 1 case (a patient with Hoehn and Yahr Scale I PD), the SPECT images were more compatible with the patient's clinical findings whereas PET showed nearly normal uptake. In the other 2 cases (both patients with Hoehn and Yahr Scale II PD), PET correlated better with the clinical findings. The caudate and putamen nuclei were more discernable on PET. An acceptable correlation of SUR, however, was found between SPECT and PET in both the striatum and the putamen (P <0.01 for both). Conclusion: The comparability of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET suggests that 99mTc-TRODAT-1 SPECT may provide a reliable alternative to 18F-FDOPA PET in the evaluation of clinical PD patients.

KW - 6-F-fluoro-L-dopa PET

KW - Tc-TRODAT-1 SPECT

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0042388390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042388390&partnerID=8YFLogxK

M3 - Article

C2 - 12843212

AN - SCOPUS:0042388390

VL - 44

SP - 999

EP - 1005

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -